Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

L Kostos; JP Buteau; J Xie; A Cardin; T Akhurst; R Alipour; L Au; J Chan; KY Chin; B Emmerson; L Furic; Q Garcia; AJ Hamilton; MB Haskali; PA Jackson; RK Kashyap; G Kong; L MacFarlane; DG Murphy; BS Parker; AS Ravi Kumar; J Saghebi; Y Wang; B Tran; AA Azad; MS Hofman

Journal article

Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

L Kostos, JP Buteau, J Xie, A Cardin, T Akhurst, R Alipour, L Au, J Chan, KY Chin, B Emmerson, L Furic, Q Garcia, AJ Hamilton, MB Haskali, PA Jackson, RK Kashyap, G Kong, L MacFarlane, DG Murphy, BS Parker Show all

Lancet Oncology | Published : 2025

DOI: 10.1016/S1470-2045(25)00559-5

Abstract

Background Lutetium-177 [177Lu]Lu-PSMA-I&T (177Lu-PSMA-I&T) and the bone-seeking α-emitter radium-223 (223Ra) are established life-extending therapies for patients with metastatic castration-resistant prostate cancer; however, resistance and progression are inevitable. We aimed to evaluate the safety and preliminary antitumour activity of 177Lu-PSMA-I&T combined with 223Ra in this patient group. Methods We conducted an investigator-initiated, single-centre, single-arm, phase 1/2 trial (AlphaBet) at the Peter MacCallum Cancer Centre in Melbourne, Australia. Adults (aged ≥18 years) with a diagnosis of progressive, metastatic castration-resistant prostate cancer, an Eastern Cooperative Oncology..

View full abstract